For people with known heart disease, lowering LDL cholesterol to under 55 mg/dL reduces the chance of heart attacks, strokes, or death by 33% within three years, and does not increase the rate of side effects compared to higher LDL targets.
See the scientific wording
In patients with established atherosclerotic cardiovascular disease, lowering LDL cholesterol to below 55 mg/dL reduces the risk of major adverse cardiovascular events by 33% over 3 years, with no increase in adverse events compared to higher LDL cholesterol targets.
Mixed evidence
Observational1 of 2 parts have evidence behind them.
Mixed evidence
1 of 2 parts have evidence behind them.
Parts of this claim
Lowering LDL cholesterol to below 55 mg/dL reduces the risk of major adverse cardiovascular events by 33% over 3 years in patients with established atherosclerotic cardiovascular disease.
Maybe1 studyAdverse event rates with lowering LDL cholesterol to below 55 mg/dL are comparable to adverse event rates with higher LDL targets in patients with established atherosclerotic cardiovascular disease.
Not testedNo studies
Evidence is judged against each part on its own, so a study that tests one part never counts as a verdict on the whole claim.
What the research says
1 study reviewedSupporting (1)
Cohort StudyHuman2026
For heart disease patients with fatty, unstable plaques in their arteries, lowering LDL cholesterol below 55 mg/dL greatly reduces the chance of heart attacks or strokes. But this benefit doesn’t seem to happen for everyone — only those with these specific dangerous plaques.
Contradicting (0)
No contradicting studies found yet
That doesn't mean it's settled — it just means no study has tested the opposite.
Quality-weighted scoring: we follow the GRADE framework — each study is rated High, Moderate, Low, or Very Low based on study design, methodology rigor, and risk of bias. A single high-quality RCT can outweigh several weaker observational studies.
Scores reflect study quality, not just count.
When LDL cholesterol drops below 55 mg/dL, less cholesterol enters the artery walls, causing fatty plaques to shrink and become less inflamed. This makes the plaques tougher and less likely to burst, which prevents blood clots that cause heart attacks and strokes.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting study
How Fit Body Science checks a claim
- 1
We isolate the claim
Health advice from videos, articles and studies is broken down into single, testable claims.
- 2
We find the research
Each claim is matched against peer-reviewed studies, with every source cited by DOI.
- 3
We grade the evidence
Studies are scored on methodology, statistical rigor, transparency and publication quality.
The fitness and health internet is full of confident claims. We check them against real research.
Every claim on this site is traced back to peer-reviewed studies, scored on methodology and reporting quality, and given a verdict you can audit yourself — sources, DOIs and all.
- Full evidence breakdown and mechanism chains
- Ask our AI anything about a claim or its studies
- Get notified when new research changes a verdict
For people with known heart disease, lowering LDL cholesterol to under 55 mg/dL reduces the chance of heart attacks, strokes, or death by 33% within three years, and does not increase the rate of side effects compared to higher LDL targets.
Mechanism
2 studiesLowering LDL cholesterol below 55 mg/dL stops fatty buildup in artery walls from becoming unstable. This makes dangerous plaques tougher and less likely to burst, which prevents heart attacks and strokes without causing other harm.
When LDL cholesterol drops below 55 mg/dL, less cholesterol enters the artery walls, causing fatty plaques to shrink and become less inflamed. This makes the plaques tougher and less likely to burst, which prevents blood clots that cause heart attacks and strokes.
LDL cholesterol levels in the blood are reduced below 55 mg/dL through inhibition of cholesterol synthesis and absorption, and increased clearance of LDL particles from circulation
Reduced circulating LDL cholesterol decreases the deposition of cholesterol into the arterial intima, particularly within lipid-rich atherosclerotic plaques
Lower lipid content in plaques reduces the recruitment and activation of macrophages, decreasing foam cell formation and the expansion of the necrotic core
Plaque inflammation diminishes as cytokine production and immune cell infiltration decline, leading to thickening of the fibrous cap over the lipid core
Stabilized plaques with thicker fibrous caps and smaller necrotic cores are resistant to rupture and do not trigger thrombus formation
Prevention of plaque rupture eliminates the primary trigger for acute thrombotic events such as myocardial infarction and ischemia-driven revascularization
Evidence from Studies
Supporting (1)
Community contributions welcome
For heart disease patients with fatty, unstable plaques in their arteries, lowering LDL cholesterol below 55 mg/dL greatly reduces the chance of heart attacks or strokes. But this benefit doesn’t seem to happen for everyone — only those with these specific dangerous plaques.
Contradicting (0)
Community contributions welcome
Score Breakdown
No multi-axis breakdown available yet. The overall Pro / Against score above is the best signal.
Clinical support requires direct evidence. Mechanistic proxy and tangential studies contribute only to the mechanistic score.
- All linked studies are tangential or mechanistic proxies — no direct test of the claim has been found.
- No clinical evidence is available; the score reflects mechanistic plausibility only.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Systematic Review and Meta-Analysis of LDL-C Lowering Below 55 mg/dL in Atherosclerotic Cardiovascular Disease
Population: Adults with established atherosclerotic cardiovascular disease; Intervention: LDL-C lowering to below 55 mg/dL via statins, PCSK9 inhibitors, or combination; Comparator: LDL-C targets above 55 mg/dL; Outcome: Major adverse cardiovascular events (cardiovascular death, myocardial infarction, stroke, unstable angina requiring hospitalization); Duration: Minimum 2 years follow-up; Analysis: Pooling of individual participant data from randomized trials.
Double-Blind Trial of Intensive LDL-C Lowering to <55 mg/dL vs Standard Target in Atherosclerotic Cardiovascular Disease
Population: Adults with documented atherosclerotic cardiovascular disease; Intervention: LDL-C lowering to <55 mg/dL using high-intensity statin and/or PCSK9 inhibitor; Comparator: LDL-C target of 70–100 mg/dL; Outcome: Composite of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, hospitalization for unstable angina; Duration: 3 years; Design: Double-blind, placebo-controlled, stratified by baseline LDL and prior event type.
Prospective Cohort Study of LDL-C Levels Below 55 mg/dL and Cardiovascular Outcomes in Real-World Atherosclerotic Disease Patients
Population: Adults with established atherosclerotic cardiovascular disease in electronic health records; Exposure: LDL-C consistently <55 mg/dL over 3 years; Comparator: LDL-C 55–100 mg/dL; Outcome: Major adverse cardiovascular events; Duration: 3 years; Analysis: Time-to-event analysis with propensity score matching for age, sex, comorbidities, and medication use.
Case-Control Study of LDL-C Levels Below 55 mg/dL in Patients With vs Without Major Adverse Cardiovascular Events
Population: Adults with established atherosclerotic cardiovascular disease; Cases: Patients with major adverse cardiovascular event within 3 years; Controls: Patients without event matched by age, sex, baseline LDL, and comorbidities; Exposure: LDL-C level below 55 mg/dL during follow-up; Duration: Retrospective 3-year window; Analysis: Conditional logistic regression adjusting for medication use and lifestyle factors.
Cross-Sectional Analysis of LDL-C Levels and Recent Cardiovascular Events in Atherosclerotic Disease Patients
Population: Adults with established atherosclerotic cardiovascular disease; Exposure: Single LDL-C measurement below 55 mg/dL; Outcome: Presence or absence of major adverse cardiovascular event within past 12 months; Duration: Single time point; Analysis: Prevalence ratios adjusted for age, sex, and statin use.